Thus, novel treatment options are needed that target downstream pathways that are activated by VEGF‐A and inhibit the pathogenic effects of increased VEGF‐A levels [e.g. choroidal neovascularization (CNV)], while maintaining the beneficial effects of VEGF‐A (e.g. neuroprotective functions of VEGF‐A), and which do not impair tissue perfusion. Here, VEGFA is linked to choroidal neovascularization.